Prosecution Insights
Last updated: August 16, 2026
Application No. 18/246,800

METHOD FOR IMPROVING HEALTH CONDITIONS

Non-Final OA §112
Filed
Mar 27, 2023
Priority
Oct 01, 2020 — JP 2020-166818 +1 more
Examiner
CABRAL, ROBERT S
Art Unit
1614
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Nissin Foods Holdings Co., Ltd.
OA Round
3 (Non-Final)
63%
Grant Probability
Moderate
3-4
OA Rounds
2y 2m
Est. Remaining
95%
With Interview

Examiner Intelligence

Grants 63% of resolved cases
63%
Career Allowance Rate
539 granted / 861 resolved
+2.6% vs TC avg
Strong +32% interview lift
Without
With
+32.4%
Interview Lift
resolved cases with interview
Typical timeline
5y 7m
Avg Prosecution
24 currently pending
Career history
891
Total Applications
across all art units

Statute-Specific Performance

§101
1.8%
-38.2% vs TC avg
§103
45.1%
+5.1% vs TC avg
§102
16.7%
-23.3% vs TC avg
§112
23.7%
-16.3% vs TC avg
Black line = Tech Center average estimate • Based on career data from 861 resolved cases

Office Action

§112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 5/15/2026, has been entered. Claims 1-6, 8, 13, 14, 18-20, 22 and 26-27 are pending. Claim 27 is new. Withdrawal of Claim Rejections Any previous rejection not reiterated herein has been withdrawn. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1-6, 8, 13, 14, 18-20, 22 and 26-27 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. The claims are indefinite for at least the following reasons. First, the claims are rejected for being prolix. Claims are rejected as prolix when they contain long recitations that the metes and bounds of the claimed subject matter cannot be determined. Claim 1 spans three pages. Second, the claims are rejected because when a limitation of the claim is defined by reference to an object and the relationship between the limitation and the object is not sufficiently defined the claims are rendered indefinite. See MPEP 2173.05(b)(II). Here, claim 1 requires adjusting meals “such that for all of the plurality of subjects . . a determined dietary intake standard for the respective segment of each of the plurality of subjects is satisfied by the each of the adjusted meals.” The claim is indefinite because the determined dietary intake standard for the respective segment of each of the plurality of subjects any of the plurality of subjects is insufficiently defined. Consequently, adjusting a meal so as to follow (i) to (iii) is rendered indefinite. Given the prolixity of the claim and the lack of standard for determining dietary intake for any particular segment, a meaningful search for prior art cannot be performed. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to ROBERT S CABRAL whose telephone number is (571)270-3769. The examiner can normally be reached M-F 8 am - 5 pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Ali Soroush can be reached at 571-272-9925. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /ROBERT S CABRAL/ Primary Examiner, Art Unit 1614
Read full office action

Prosecution Timeline

Mar 27, 2023
Application Filed
Jul 11, 2025
Non-Final Rejection mailed — §112
Dec 08, 2025
Response Filed
Jan 16, 2026
Final Rejection mailed — §112
Mar 26, 2026
Interview Requested
May 15, 2026
Request for Continued Examination
May 19, 2026
Response after Non-Final Action
Jun 24, 2026
Non-Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12702674
Methods For Producing Chemoembolic Agents For The Delivery Of Anti-Cancer Agents
5y 8m to grant Granted Aug 11, 2026
Patent 12703637
FUNCTIONALIZED SILICA NANORINGS, METHODS OF MAKING SAME, AND USES THEREOF
4y 11m to grant Granted Aug 11, 2026
Patent 12702703
EDIBLE PLANT EXOSOME-LIKE NANOVECTORS FOR VACCINATION
3y 12m to grant Granted Aug 11, 2026
Patent 12703856
METHODS FOR REDUCING ELEVATED GLUCOSE LEVELS
2y 4m to grant Granted Aug 11, 2026
Patent 12678518
A Theranostic Probe and its Use for Targeting and/or Labeling the EGFR Kinase and/or the Cells Expressing EGFR or its Family Members
4y 1m to grant Granted Jul 14, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
63%
Grant Probability
95%
With Interview (+32.4%)
5y 7m (~2y 2m remaining)
Median Time to Grant
High
PTA Risk
Based on 861 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month